Nektar Therapeutics will announce its financial results for the third quarter ending September 30, 2026, on November 12 after U.S. markets close. CEO Howard Robin will host a conference call to discuss the results at 5:00 p.m. Eastern Time. The call will be webcast live and available for replay until December 12. Nektar is a biotech company developing treatments for autoimmune and inflammatory diseases, with key drug candidates in clinical and preclinical stages.
Nektar Therapeutics will announce its Q3 financial results on November 12, 2026, after U.S. markets close. For readers following the health sector, here is Pluang's market snapshot as of Oct 28, 2026 05:02 WIB: out of 150 priced US health stocks, 90 rose and 60 fell. Notable movers include MESO at USD 13.18 with a 6.38% gain and a typical hold time of 17 days, RXRX at USD 4.04 with a 6.32% gain but 99% sell order activity, and DYN at USD 16.61 with a 5.66% gain and a typical hold time of 6 days.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Pomerantz LLP is investigating Mueller Industries for potential securities fraud following the company's Q3 fiscal 2026 earnings report, which showed earnings per share of $1.00, below analyst estimates of $1.05 to $1.08. The company also reported a ...
Silvercorp Metals announced a 13% decline in preliminary Q2 revenue to $72.1 million, caused by significant production shortfalls at its Ying Mining District due to safety upgrades. Silver, lead, and zinc outputs fell sharply by 41%, 41%, and 51% res...
Lufax Holding Ltd posted a net loss of RMB1.49 billion in Q3 2026, up from RMB380 million a year earlier, driven by increased credit impairment losses and higher income tax expenses. Total income slightly declined by 4.6% to RMB6.18 billion, while ne...
Tenax Therapeutics is facing a class action lawsuit alleging it misled investors about the effectiveness of its drug TNX-103 for pulmonary hypertension. The lawsuit claims the company overstated the drug's clinical and commercial prospects, leading t...
